These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.
    Author: Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ.
    Journal: Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1323-31. PubMed ID: 21050234.
    Abstract:
    BACKGROUND: On-treatment predictors of response to peginterferon can guide individualization of therapy in chronic hepatitis B virus infection. AIM: To investigate the use of serum hepatitis B surface antigen quantification to predict sustained response. METHODS: Hepatitis B e antigen-positive chronic hepatitis B patients who received peginterferon for 32-48 weeks with or without lamivudine combination were studied. Sustained response was defined as hepatitis B e antigen seroconversion and chronic hepatitis B virus DNA <10 000 copies/mL until 12 months post-treatment. RESULTS: Twenty-one of 92 (23%) patients achieved sustained response. At month 6, the area under receiver operating characteristics curve for hepatitis B surface antigen to predict sustained response was 0.77 (95% confidence interval 0.65-0.89, P < 0.001). An hepatitis B surface antigen cutoff at 300 IU/mL at month 6 could give the maximum combination of sensitivity (62%) and specificity (89%) to predict sustained response. Nine of 21 (43%) sustained responders vs. 9 of 71 (13%) nonsustained responders had >1 log hepatitis B surface antigen reduction at month 6 (P < 0.001). Combined hepatitis B surface antigen ≤ 300 IU/mL and >1 log reduction at month 6 had sensitivity, specificity, positive and negative predictive values of 43%, 96%, 75% and 85% to predict sustained response, respectively. CONCLUSION: On-treatment serum hepatitis B surface antigen can predict response to peginterferon therapy in chronic hepatitis B.
    [Abstract] [Full Text] [Related] [New Search]